Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 91, Issue -, Pages 946-950Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2017.05.024
Keywords
(-)-alpha-Bisabolol; Nanocapsules; Corneal pain; TRPV1
Funding
- CNPq [310081/2011-4]
- Funcap [12535647-1]
- Capes [053/14]
Ask authors/readers for more resources
This study aimed to develop and to evaluate the antinociceptive effect of a drug delivery system containing (-)-alpha-bisabolol (BISA). Nanocapsules containing BISA (BISA-NC) were prepared using acetylated galatomannan. Particle size distribution was determined by atomic force microscopy, zeta potential measurement and photon correlation spectroscopy. Corneal nociception was induced by topical application of 5 M NaCl and the nociceptive behavior was characterized by eye wiping in mice. Molecular docking was conducted on the TRPV1 channel. Nanocapsules showed mean particle sizes between 94.44 and 105.44 nm and the zeta potential of was - 1.34 mV. Animals pretreated with BISA-NC (200 mg/mL) had a significant reduction (**p < 0.01) in the number of nociceptive behaviors. Docking study indicated an interaction between BISA and TRPV1. This study indicates that BISA-NC may be useful for producing eye drops for the treatment of ocular pain. (C) 2017 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available